Study on the Critical Quality Attribute of Anti-HER2 Monoclonal Antibody

Wang Xin, Chen Weidong

Chinese Pharmaceutical Affairs ›› 2024, Vol. 38 ›› Issue (9) : 1043-1052.

Chinese Pharmaceutical Affairs ›› 2024, Vol. 38 ›› Issue (9) : 1043-1052. DOI: 10.16153/j.1002-7777.20240424
Regulatory Technology

Study on the Critical Quality Attribute of Anti-HER2 Monoclonal Antibody

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2024, 38(9): 1043-1052 https://doi.org/10.16153/j.1002-7777.20240424

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉